Biodexa Pharmaceuticals Plc Overview

Biodexa Pharmaceuticals Plc Selling, General & Admin

Selling, General & Admin expenses for BDRX.

Quarterly SG&A Expenses

$2.39M

↑ 36.11% YoY

As of Dec 31, 2025

Annual SG&A Expenses (TTM)

$7.55M

↑ 159.97% YoY

Trailing 12 months ending Dec 31, 2025

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin